Home / Business and Economy / Blackstone and TPG Acquire Hologic in Landmark $18.3B Deal
Blackstone and TPG Acquire Hologic in Landmark $18.3B Deal
21 Oct
Summary
- Blackstone and TPG agree to acquire Hologic for up to $18.3 billion
- Shareholders to receive $76 per share in cash, plus potential $3 per share contingent on revenue goals
- Hologic specializes in women's health diagnostics, including cancer screening and infectious disease testing
On October 21, 2025, it was announced that private equity firms Blackstone and TPG have agreed to acquire medical diagnostics company Hologic in a deal valued at up to $18.3 billion. Under the terms of the agreement, Blackstone and TPG will pay $76 per share in cash to acquire all outstanding Hologic shares, representing a premium of nearly 6% to the stock's last closing price.
Additionally, Hologic shareholders will be eligible to receive a non-tradable right to receive up to $3 per share, contingent on certain global revenue goals for the company's breast health business in fiscal years 2026 and 2027. This brings the total potential payout to $79 per share.
Hologic is a leading provider of women's health diagnostics, specializing in areas such as breast and cervical cancer screening, as well as infectious disease testing. The company has seen steady growth in its molecular diagnostics business and reported strong financial results, though it has also faced continued weakness in its breast health segment.
The acquisition is expected to close in the first half of 2026, subject to regulatory approvals and other customary closing conditions. The deal marks one of the largest healthcare take-private transactions of the year, underscoring the continued interest in the diagnostics and healthcare technology sectors from private equity investors.
